A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...
ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...
PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...
A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...
